NIKKEI 225
38,267.60 -567.50 (-1.46%) HANG SENG
18,410.20 -69.17 (-0.37%) CRUDE OIL
78.07 -0.31 (-0.40%) GOLD FUTURES
2,326.50 +2.30 (+0.10%) DOW
38,884.26 +31.99 (+0.08%) Bitcoin GBP
50,259.13 -506.96 (-1.00%)
Mauna Kea Technologies SA (0P5I.L)
| Previous close | 0.3890 |
| Open | 0.0000 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.0000 - 0.0000 |
| 52-week range | |
| Volume | |
| Avg. volume | 442 |
| Market cap | 119,565 |
| Beta (5Y monthly) | 1.38 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.3530 |
| Earnings date | 25 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Mauna Kea Technologies Announces 9 Presentations Demonstrating the Clinical Value of Cellvizio® at Digestive Disease Week® 2024
PARIS & BOSTON, May 06, 2024--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced the presentation of 9 abstracts supporting Cellvizio® at the Digestive Disease Week® (DDW) Conference, being held on May 18-21, 2024 in Washington, DC. These abstracts focus on artificial intelligence, pancreatic cystic lesions and pancreatic cancer, food intolerance an
- Business Wire
Mauna Kea Technologies: Publication of the 2023 Annual Financial Report
PARIS & BOSTON, April 30, 2024--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT) (Paris:ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced that it has published its Annual Financial Report for the year ended 31 December 2023 and filed it with the Autorité des Marchés Financiers (AMF) on 30 April 2024.
- Business Wire
Mauna Kea Technologies Announces the Opening of a French Center of Excellence for the Use of Cellvizio® in Lung Cancer Diagnostics
PARIS & BOSTON, April 29, 2024--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT) (Paris:ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced the opening of a French Center of Excellence for the use of Cellvizio in lung cancer diagnostics. The Cellvizio procedure is now performed preoperatively by Prof. Stéphane Renaud, MD, PhD, a leading thoracic surgeon at the University Hospital (CHRU) in N
